On November 17, 2026, Planet Green Holdings Corp. announced that its wholly-owned subsidiary, Hubei Taihe Biotechnology Co., Ltd., entered into a technology transfer agreement with Harbin Aikesailun Biotechnology Co., Ltd.
Under the agreement, Taihe Bio will acquire the rights to a registered immune-support health food product known as Aikesailun-branded bovine colostrum, vitamin C, and lactoferrin chewable tablets. The transaction includes the proprietary formulation, production process, quality standards, and related technical know-how, as well as the associated health food registration certificate rights in China.
Taihe Bio agreed to pay RMB 1,550,000 (approximately US$232,500) to Aikesailun Bio. The subsidiary is also responsible for certain transfer-related costs, including notarization, sample production, and testing. Aikesailun Bio will provide technical materials and assistance with the transfer and registration process, with the parties jointly applying to China’s State Administration for Market Regulation to transfer the registration certificate.
Planet Green stated that the acquisition is intended to extend its lactoferrin strategy and strengthen its immunity product pipeline. The company noted that the Product combines lactoferrin with bovine colostrum and vitamin C. The press release accompanying the filing highlighted that the Product is already registered in China and that Taihe Bio intends to use licensed contract manufacturers rather than build its own production facilities.